
Episode 14: Aditum Bio's Joe Jimenez
BioVenture VoiCes with Chris Garabedian
00:00
Cell, gene and radioligand investments
Joe touches on Novartis' cell/gene strategy and the strategic bet on radioligand therapy.
Play episode from 40:03
Transcript


